Advanced search
Publication Cover
OncoImmunology Volume 6, 2017 - Issue 3
Submit an article Journal homepage
2,176
Views
45
CrossRef citations to date
0
Altmetric
Original Research

PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma

Jan BudcziesInstitute of Pathology, Charité University Hospital, Berlin, Germany;German Cancer Consortium (DKTK), partner sites Heidelberg and Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany
,
Gunhild MechtersheimerInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
,
Carsten DenkertInstitute of Pathology, Charité University Hospital, Berlin, Germany;German Cancer Consortium (DKTK), partner sites Heidelberg and Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany
,
Frederick KlauschenInstitute of Pathology, Charité University Hospital, Berlin, Germany
,
Sadaf S. MughalDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT) Heidelberg, Heidelberg, GermanyORCID Iconhttp://orcid.org/0000-0003-3468-8467
ORCID Icon,
Priya ChudasamaDepartment of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, GermanyORCID Iconhttp://orcid.org/0000-0002-0754-4436
ORCID Icon,
Michael BockmayrInstitute of Pathology, Charité University Hospital, Berlin, GermanyORCID Iconhttp://orcid.org/0000-0002-9249-4292
ORCID Icon,
Korinna JöhrensInstitute of Pathology, Charité University Hospital, Berlin, Germany
,
Volker EndrisInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
,
Amelie LierInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
,
Felix LasitschkaInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
,
Roland PenzelInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
,
Manfred DietelInstitute of Pathology, Charité University Hospital, Berlin, Germany;German Cancer Consortium (DKTK), partner sites Heidelberg and Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany
,
Benedikt BrorsGerman Cancer Consortium (DKTK), partner sites Heidelberg and Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany;Division of Applied Bioinformatics, German Cancer Research Center (DKFZ) and National Center for Tumor Disease (NCT) Heidelberg, Heidelberg, Germany
,
Stefan GröschelDepartment of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany;Section for Personalized Oncology, Heidelberg University Hospital, Heidelberg, Germany
,
Hanno GlimmGerman Cancer Consortium (DKTK), partner sites Heidelberg and Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany;Department of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany;Section for Personalized Oncology, Heidelberg University Hospital, Heidelberg, Germany
,
Peter SchirmacherGerman Cancer Consortium (DKTK), partner sites Heidelberg and Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany;Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
,
Marcus RennerInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
,
Stefan FröhlingGerman Cancer Consortium (DKTK), partner sites Heidelberg and Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany;Department of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany;Section for Personalized Oncology, Heidelberg University Hospital, Heidelberg, Germany
&
Albrecht StenzingerGerman Cancer Consortium (DKTK), partner sites Heidelberg and Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany;Institute of Pathology, University Hospital Heidelberg, Heidelberg, GermanyCorrespondence[email protected]
 show all
Article: e1279777 | Received 01 Aug 2016, Accepted 04 Jan 2017, Published online: 07 Mar 2017

Citations (45)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Qingling Hua, Guojie Xu, Lei Zhao & Tao Zhang. (2021) Comparison of first line chemotherapy regimens for advanced soft tissue sarcoma: a network meta-analysis. Journal of Chemotherapy 33:8, pages 570-581.
Read now
Jay S. Wunder, Minji J. Lee, Junghyun Nam, Beatrice Y. Lau, Brendan C. Dickson, Dushanthi Pinnaduwage, Shelley B. Bull, Peter C. Ferguson, Andrew Seto, Nalan Gokgoz & Irene L. Andrulis. (2020) Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation. OncoImmunology 9:1.
Read now
Sarah Lévesque, Julie Le Naour, Federico Pietrocola, Juliette Paillet, Margerie Kremer, Francesca Castoldi, Elisa E. Baracco, Yan Wang, Erika Vacchelli, Gautier Stoll, Ariane Jolly, Pierre De La Grange, Laurence Zitvogel, Guido Kroemer & Jonathan G. Pol. (2019) A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. OncoImmunology 8:11.
Read now
Qi Chen, Tianhe Li & Wentao Yue. (2018) Drug response to PD-1/PD-L1 blockade: based on biomarkers. OncoTargets and Therapy 11, pages 4673-4683.
Read now
Marie Kostine, Inge H. Briaire-de Bruijn, Arjen H. G. Cleven, Carly Vervat, Willem E. Corver, Marco W. Schilham, Els Van Beelen, Hester van Boven, Rick L. Haas, Antoine Italiano, Anne-Marie Cleton-Jansen & Judith V. M. G. Bovée. (2018) Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. OncoImmunology 7:2.
Read now
Emily Z. Keung, Jen-Wei Tsai, Ali M. Ali, Janice N. Cormier, Andrew J. Bishop, B. Ashleigh Guadagnolo, Keila E. Torres, Neeta Somaiah, Kelly K. Hunt, Jennifer A. Wargo, Alexander J. Lazar, Wei-Lien Wang & Christina L. Roland. (2018) Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. OncoImmunology 7:2.
Read now

Articles from other publishers (39)

Marium Husain, Dionisia Quiroga, Han Gil Kim, Scott Lenobel, Menglin Xu, Hans Iwenofu, James L. Chen, Claire Verschraegen, David Liebner & Gabriel Tinoco. (2023) Clinical markers of immunotherapy outcomes in advanced sarcoma. BMC Cancer 23:1.
Crossref
Zhiyong Liu, Xin Wang, Jiaqiang Wang, Peng Zhang, Chao Li, Bangmin Wang, Songtao Gao, Oufei Liu & Weitao Yao. (2023) The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study. Frontiers in Oncology 13.
Crossref
Lauren M Perry, Sylvia M Cruz, Kara T Kleber, Sean J Judge, Morgan A Darrow, Louis B Jones, Ugur N Basmaci, Nikhil Joshi, Matthew L Settles, Blythe P Durbin-Johnson, Alicia A Gingrich, Arta Monir Monjazeb, Janai Carr-Ascher, Steve W Thorpe, William J Murphy, Jonathan A Eisen & Robert J Canter. (2023) Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis. Journal for ImmunoTherapy of Cancer 11:1, pages e004285.
Crossref
Mingjing Peng, Songqing Fan, Junjun Li, Xiao Zhou, Qianjin Liao, Faqing Tang & Wei Liu. (2022) Programmed death-ligand 1 signaling and expression are reversible by lycopene via PI3K/AKT and Raf/MEK/ERK pathways in tongue squamous cell carcinoma. Genes & Nutrition 17:1.
Crossref
Antonia Resag, Giulia Toffanin, Iva Benešová, Luise Müller, Vlatko Potkrajcic, Andrej Ozaniak, Robert Lischke, Jirina Bartunkova, Antonio Rosato, Korinna Jöhrens, Franziska Eckert, Zuzana Strizova & Marc Schmitz. (2022) The Immune Contexture of Liposarcoma and Its Clinical Implications. Cancers 14:19, pages 4578.
Crossref
Kristian Larson, Atlantis Russ, Hina Arif-Tiwari, Daruka Mahadevan, Alex Elliott, Achyut Bhattacharyya & Hani Babiker. (2022) Pembrolizumab Achieves a Complete Response in an NF-1 Mutated, PD-L1 Positive Malignant Peripheral Nerve Sheath Tumor: A Case Report and Review of the Benchmarks. Journal of Immunotherapy 45:4, pages 222-226.
Crossref
Kazuhiko Hashimoto, Shunji Nishimura, Tomohiko Ito, Ryosuke Kakinoki & Masao Akagi. (2022) Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas. European Journal of Histochemistry 66:2.
Crossref
Shadi Hames-Fathi, Steven W G Nottley & Nischalan Pillay. (2021) Unravelling undifferentiated soft tissue sarcomas: insights from genomics. Histopathology 80:1, pages 109-121.
Crossref
Bahador Oshidari, Amir Zamani, Hooman Bahrami-Motlagh, Elena Jamali, Setareh Mahmoodi & Manoochehr Ebrahimian. (2022) Primary leiomyosarcoma of the adrenal; a case report. International Journal of Surgery Case Reports 90, pages 106707.
Crossref
Matthieu Roulleaux Dugage, Elise F. Nassif, Antoine Italiano & Rastislav Bahleda. (2021) Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Frontiers in Immunology 12.
Crossref
Ottavia Clemente, Alessandro Ottaiano, Giuseppe Di Lorenzo, Alessandra Bracigliano, Sabrina Lamia, Lucia Cannella, Antonio Pizzolorusso, Massimiliano Di Marzo, Mariachiara Santorsola, Annarosaria De Chiara, Flavio Fazioli & Salvatore Tafuto. (2021) Is immunotherapy in the future of therapeutic management of sarcomas?. Journal of Translational Medicine 19:1.
Crossref
Jason Roszik, Lisa Maria Mustachio, John A. Livingston, Roman Groisberg, Roberto Carmagnani Pestana, Vivek Subbiah & Anthony P. Conley. (2021) Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma. Cancers 13:20, pages 5249.
Crossref
Luana Madalena Sousa, Jani Sofia Almeida, Tânia Fortes-Andrade, Manuel Santos-Rosa, Paulo Freitas-Tavares, José Manuel Casanova & Paulo Rodrigues-Santos. (2021) Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy. Cancers 13:15, pages 3885.
Crossref
Kazuhiko Hashimoto, Shunji Nishimura, Tomohiko Ito & Masao Akagi. (2021) Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas. European Journal of Histochemistry 65:3.
Crossref
Mohamed Kelany, Thomas FE. Barth, Dina Salem & Marwa M. Shakweer. (2021) Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas. Pathology and Oncology Research 27.
Crossref
Serena Pillozzi, Andrea Bernini, Ilaria Palchetti, Olivia Crociani, Lorenzo Antonuzzo, Domenico Campanacci & Guido Scoccianti. (2021) Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level. Cancers 13:12, pages 3044.
Crossref
Rangarirai Makuku, Neda Khalili, Sepideh Razi, Mahsa Keshavarz-Fathi & Nima Rezaei. (2021) Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy. Journal of Immunology Research 2021, pages 1-15.
Crossref
Yi Luo, Li Min, Yong Zhou, Fan Tang, Minxun Lu, Hongmei Xie, Yitian Wang, Hong Duan, Wenli Zhang & Chongqi Tu. (2021) Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient. Medicine 100:12, pages e25262.
Crossref
Jing Yang, Meilian Dong, Yifang Shui, Yue Zhang, Zhigang Zhang, Yin Mi, Xiaoxiao Zuo, Li Jiang, Ke Liu, Zheyan Liu, Xiaobin Gu & Yonggang Shi. (2020) A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients. Cancer Cell International 20:1.
Crossref
Dionisia Quiroga, David A. Liebner, Jennifer S. Philippon, Sarah Hoffman, Yubo Tan, James L. Chen, Scott Lenobel, Paul E. WakelyJrJr, Raphael Pollock & Gabriel Tinoco. (2020) Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis. BMC Cancer 20:1.
Crossref
Mayanne M.T. Zhu, Elahe Shenasa & Torsten O. Nielsen. (2020) Sarcomas: Immune biomarker expression and checkpoint inhibitor trials. Cancer Treatment Reviews 91, pages 102115.
Crossref
Katie Hudson, Neil Cross, Nicola Jordan-Mahy & Rebecca Leyland. (2020) The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Frontiers in Immunology 11.
Crossref
Feng Wang, Tao Yu, Chengbin Ma, Hongmou Yuan, Haifei Zhang & Zhiyu Zhang. (2020) Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients. Frontiers in Oncology 10.
Crossref
Jin Liang, Dedian Chen, Liyao Chen, Xueke She, Hushan Zhang & Yanbin Xiao. (2020) The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers. Future Oncology 16:17, pages 1211-1223.
Crossref
Ana Cristina Vargas, Fiona M. Maclean, Loretta Sioson, Dinh Tran, Fiona Bonar, Annabelle Mahar, Alison L. Cheah, Peter Russell, Peter Grimison, Louise Richardson & Anthony J. Gill. (2020) Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes. PLOS ONE 15:4, pages e0222551.
Crossref
Emily Z. Keung, Melissa Burgess, Ruth Salazar, Edwin R. Parra, Jaime Rodrigues-Canales, Vanessa Bolejack, Brian A. Van Tine, Scott M. Schuetze, Steven Attia, Richard F. Riedel, James Hu, Scott H. Okuno, Dennis A. Priebat, Sujana Movva, Lara E. Davis, Damon R. Reed, Alexandre Reuben, Christina L. Roland, Denise Reinke, Alexander J. Lazar, Wei-Lien Wang, Jennifer A. Wargo & Hussein A. Tawbi. (2020) Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clinical Cancer Research 26:6, pages 1258-1266.
Crossref
Hui-Yun Gu, Chao Zhang, Jia Guo, Min Yang, Hou-Cheng Zhong, Wei Jin, Yang Liu, Li-Ping Gao & Ren-Xiong Wei. (2020) Risk score based on expression of five novel genes predicts survival in soft tissue sarcoma. Aging 12:4, pages 3807-3827.
Crossref
Barbara Seliger. (2019) Basis of PD1/PD-L1 Therapies. Journal of Clinical Medicine 8:12, pages 2168.
Crossref
Berna C. Özdemir, Pierre Bohanes, Bettina Bisig, Edoardo Missiaglia, Petros Tsantoulis, George Coukos, Michael Montemurro, Krisztian Homicsko & Olivier Michielin. (2019) Deep Response to Anti-PD-1 Therapy of Metastatic Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumor With CD274/PD-L1 Amplification . JCO Precision Oncology:3, pages 1-6.
Crossref
Amanda R. Dancsok, Nokitaka Setsu, Dongxia Gao, Jean-Yves Blay, David Thomas, Robert G. Maki, Torsten O. Nielsen & Elizabeth G. Demicco. (2019) Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. Modern Pathology 32:12, pages 1772-1785.
Crossref
Xiangfeng Shen, Lihong Zhang, Jicheng Li, Yulin Li, Yishu Wang & Zhi-Xiang Xu. (2019) Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. Frontiers in Immunology 10.
Crossref
Panagiotis Tsagozis, Martin Augsten, Yifan Zhang, Tian Li, Asle Hesla, Jonas Bergh, Felix Haglund, Nicholas P. Tobin & Monika Ehnman. (2019) An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma. Cancer Immunology, Immunotherapy 68:6, pages 927-936.
Crossref
Lai Man Natalie Wu & Qing Richard Lu. (2019) Therapeutic targets for malignant peripheral nerve sheath tumors. Future Neurology 14:1, pages FNL7.
Crossref
Kelly A. Devereaux, Vivek Charu, Shuchun Zhao, Gregory W. Charville, Charles D. Bangs, Matt van de Rijn, Athena M. Cherry & Yasodha Natkunam. (2018) Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies. Human Pathology 82, pages 39-45.
Crossref
Chao-Qun Liu, Jing Xu, Zhong-Guo Zhou, Li-Lian Jin, Xing-Juan Yu, Gang Xiao, Jie Lin, Shi-Mei Zhuang, Yao-Jun Zhang & Limin Zheng. (2018) Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. British Journal of Cancer 119:1, pages 80-88.
Crossref
Chuanxi Zheng, Wei You, Peng Wan, Xiaochun Jiang, Jinquan Chen, Yuchen Zheng, Wei Li, Jifeng Tan & Shiquan Zhang. (2018) Clinicopathological and prognostic significance of PD-L1 expression in sarcoma. Medicine 97:25, pages e11004.
Crossref
Ana Sebio, Breelyn A Wilky, Vicki L Keedy & Robin L Jones. (2018) The current landscape of early drug development for patients with sarcoma in the immunotherapy era. Future Oncology 14:12, pages 1197-1211.
Crossref
Federico Pio Fabrizio, Domenico Trombetta, Antonio Rossi, Angelo Sparaneo, Stefano Castellana & Lucia Anna Muscarella. (2018) Gene code CD274/PD-L1 : from molecular basis toward cancer immunotherapy . Therapeutic Advances in Medical Oncology 10, pages 175883591881559.
Crossref
Delong Liu, Shuhang Wang & Wendy Bindeman. (2017) Clinical applications of PD-L1 bioassays for cancer immunotherapy. Journal of Hematology & Oncology 10:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.